Navigation Links
Researchers Urge Caution in Using ESAs for Cancer-Related Anemia

Drugs Might Increase Risk of Tumor Growth, Data Suggest

DURHAM, N.C., April 30, 2007 /PRNewswire/ -- Echoing recent FDA warnings, a research group from Northern Ireland cautions against over-aggressive use of a group of drugs called "erythropoiesis-stimulating agents" (ESAs) to treat anemia in some cancer patients, according to a commentary in the April issue of The Oncologist, published by AlphaMed Press.

The article by Dr. Terence R. Lappin and colleagues of Queen's University, Belfast, cites evidence that using ESAs to treat non-chemotherapy-related anemia in cancer patients could increase the risk of death, thromboembolic events, and perhaps even cancer growth. The authors write, "Overall these studies have raised concerns that ESAs could in certain circumstances adversely affect survival in cancer patients and have led to speculation that these agents may enhance thrombosis, tumor growth, and neovascularization."

The ESAs darbepoetin alfa (Aranesp) and epoetin alfa (Epogen and Procrit) are genetically engineered forms of a protein called erythropoietin, which stimulates red blood cell production. The drugs are widely used to treat anemia: low levels of hemoglobin, the oxygen-carrying protein in the blood. They are approved for use in treating anemia in patients with chronic kidney disease and in cancer patients with anemia related to chemotherapy.

However, the FDA has recently issued alerts regarding possible hazards of ESA treatment for anemia in cancer patients not receiving chemotherapy. The alerts were based on problems reported in several studies of such "off-label" use of ESAs. One study showed a 25 percent increase in the risk of death for patients receiving darbepoetin alfa. Another reported that cancer patients treated with ESAs were at much higher risk of abnormal blood clots, or "thromboembolic events" -- including stroke and myocardial infarction.

In their commentary , Dr. Lappin and coauthors draw attention to an additional possibility: that ESAs could promote cancer growth. Several studies have identified molecular receptors of erythropoietin in the endothelial cells lining blood vessels and possibly in tumor cells as well. Because of their genetically modified characteristics, ESAs may have stronger effects on these receptors than natural erythropoietin does. If so, then it is possible that ESAs may promote abnormal formation of new blood vessels. This process, called neovascularization, is a key event in cancer growth and progression.

To clarify the adverse effects of ESA treatment in cancer patients, it will be necessary to find out more about how the erythropoietin receptor functions in cancers, the authors believe. Recent studies at their laboratory suggest that erythropoietin may have abnormal effects on the erythropoietin receptors in cultured tumor cells. If this also happens in tumor tissues, it may contribute to the adverse effects of ESAs in patients with cancer-related anemia.

Pending further scientific data, a closer look at the available clinical research may offer important insights. Studies in patients with kidney disease have suggested that using erythropoietin to raise hemoglobin above the usual target level of 12 grams per deciliter (g/dL) is not helpful, and possibly harmful.

"Additional research is urgently needed to determine the effects of ESAs on risk of thrombosis, rate of tumor growth and neovascularization both in vitro and in vivo," Dr. Lappin and colleagues write. Until such studies are done, they believe that ESA treatment for cancer-related anemia should be undertaken cautiously -- and no higher than the 12 g/dL target level.

The new article, entitled, "Warning Flags for Erythropoiesis Stimulating Agents and Cancer Associated Anemia," is available online at http://theoncologist.alphamedpress.org and in print in the April issue of The Oncologist.

About AlphaMed Press

AlphaMed Press publishes the internationally renowned journals Stem Cells and The Oncologist. Stem Cells, now in its 25th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. The Oncologist, in its 12th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the care of cancer patients. Its highly acclaimed CME program, The Oncologist CME Online, has awarded more than 28,500 AMA PRA Category 1 Credits(TM). View AlphaMed Press journals at http://www.alphamedpress.org.

Contact: George Kendall: 919-680-0011, . GKendall@alphamedpress.com

CONTACT: George Kendall of The AlphaMed Company, Inc., +1-919-680-0011, GKendall@alphamedpress.com

Web site: http://www.theoncologist.com/http://www.alphamedpress.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Researchers Discover Method for Identifying How Cancer Evades the Immune System
4. Researchers Discover Gene For Rare Skin Disorder
5. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
6. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
7. Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain
8. Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report
9. World First Medical Treatment Announced by Researchers at Queen Mary University London and University of Leicester
10. Researchers Identify New Genetic Risk Factors for Type 2 Diabetes
11. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):